Emerging Markets’ Rising Spending Seen Driving Generic Growth
This article was originally published in PharmAsia News
Executive Summary
The US has long been the Indian generic drug industry’s biggest market but developing markets are also now emerging as important customers. Helped by acquisitions, geographic expansion and a steadily expanding product portfolio, India’s top 10 pharma companies notched up a 21% CAGR in emerging market revenues from fiscal 2011-15, a new report says.